EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum

Jaime Fernández Arias iD, Wagner S Brum, Gemma Salvadó iD, Joseph Therriault, Stijn Servaes, Yi-Ting Wang iD, Etienne Aumont, Nesrine Rahmouni, Arthur C Macedo, Kely Monica Quispialaya, Seyyed Ali Hosseini, Peter Kunach und 28 weitere

Brain · 07.07.2025 · 148 (7) · 2384-2399

DOI: 10.1093/brain/awaf033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 29.01.2025. Verfasst von Jaime Fernández Arias und 39 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neuroimaging Laboratory, Montreal Neurological Institute, Montreal, Quebec H3A 2B4, Canada. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Memory Disorders. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, 'La Caixa' Foundation, ‘La Caixa’ Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma phosphorylated tau (p-tau) biomarkers open unprecedented opportunities for identifying carriers of Alzheimer’s disease pathophysiology in early disease stages using minimally invasive techniques. Plasma p-tau biomarkers are believed to reflect tau phosphorylation and secretion. However, it remains unclear to what extent the magnitude of plasma p-tau abnormalities reflects neuronal network disturbance in the form of cognitive impairment. To address this question, we included 103 cognitively unimpaired elderly and 40 cognitively impaired, amyloid-β-positive individuals from the TRIAD cohort, in addition to 336 cognitively unimpaired and 216 cognitively impaired, amyloid-β-positive older adults from the BioFINDER-2 cohort. Participants had tau PET scans, amyloid PET scans or amyloid CSF, p-tau217, p-tau181 and p-tau231 blood measures, structural T1-MRI and cognitive assessments. In this cross-sectional study, we used regression models and correlation analyses to assess the relationship between plasma biomarkers and cognitive scores. Furthermore, we applied receiver operating characteristic curves to assess cognitive impairment across plasma biomarkers. Finally, we categorized participants into amyloid (A), p-tau (T1) and tau PET (T2) positive (+) or negative (−) profiles and ran non-parametric comparisons to assess differences across cognitive domains. We found that plasma p-tau217 was more associated with cognitive performance than p-tau181 and p-tau231 and that this relationship was particularly strong for memory scores (TRIAD: βp-tau217 = −0.53, βp-tau181 = −0.35 and βp-tau231 = −0.24; BioFINDER-2: βp-tau217 = −0.52, βp-tau181 = −0.24 and βp-tau231 = −0.29). Associations in amyloid-β-positive participants resembled these results, but other cognitive scores also showed strong associations in cognitively impaired individuals. Moreover, plasma p-tau217 outperformed plasma p-tau181 and plasma p-tau231 in identifying memory impairment (area under the curve values for TRIAD: p-tau217 = 0.86, p-tau181 = 0.77 and p-tau231 = 0.75; and for BioFINDER-2: p-tau217 = 0.86, p-tau181 = 0.76 and p-tau231 = 0.81) and in identifying executive function impairment only in the BioFINDER-2 cohort (p-tau217 = 0.82, p-tau181 = 0.76 and p-tau231 = 0.76). Lastly, we showed that subtle memory deficits were present in A+T1+T2− participants for plasma p-tau217 (P = 0.007) and plasma p-tau181 (P = 0.01) in the TRIAD cohort and for all biomarkers across cognitive domains in A+T1+T2− and A+T1+T2− individuals (P < 0.001 in all) in the BioFINDER-2 cohort. The A+T1+T2− individuals showed cognitive deficits in both cohorts (P < 0.001 in all). Together, our results suggest that plasma p-tau217 stands out as a biomarker capable of identifying memory deficits attributable to Alzheimer’s disease and that memory impairment certainly occurs in amyloid-β- and plasma p-tau-positive individuals who have no significant amounts of tau in the neocortex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseMemory DisordersHumansMaleFemaleAgedPhosphorylationBiomarkersCross-Sectional StudiesAged, 80 and overAmyloid beta-PeptidesPositron-Emission TomographyCognitive DysfunctionCohort StudiesMiddle AgedMagnetic Resonance Imaging

Stichwörter der Autor:innen

Alzheimer’s diseasememoryplasma p-tau217tau discordance

Substanzen

tau ProteinsBiomarkersAmyloid beta-PeptidesMAPT protein, human

Autor:innen und Institutionen

  • Translational Neuroimaging Laboratory, Montreal Neurological Institute, Montreal, Quebec H3A 2B4, Canada.
  • Department of Neurology and Neurosurgery, McGill University Research Centre for Studies in Aging, Verdun, Quebec H4H 1R3, Canada.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 41390, Sweden.
  • Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90010-150, Brazil.
  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund 22184, Sweden.
  • Faculty of Medicine, McGill University, Montreal, Quebec H3G 2M1, Canada.

ORCID-Profile: Jaime Fernández Arias, Gemma Salvadó, Yi-Ting Wang, Paolo Vitali, Gleb Bezgin, Eduardo R Zimmer, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Henrik Zetterberg, Oskar Hansson, Pedro Rosa-Neto

Förderung

  • NIA NIH HHS
  • 'La Caixa' Foundation
  • ‘La Caixa’ Foundation

Zitieren

APA

Fernández Arias, J., Brum, W. S., Salvadó, G., Therriault, J., Servaes, S., Wang, Y. T., Aumont, E., Rahmouni, N., Macedo, A. C., Quispialaya, K. M., Hosseini, S. A., Kunach, P., Jia, W. L., Chan, T., Trudel, L., Hall, B., Zheng, Y., Mohapatra, S., Mathotaarachchi, S. S., …, & Rosa-Neto, P. (2025). Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum. Brain, 148(7), 2384-2399. https://doi.org/10.1093/brain/awaf033

Vancouver

Fernández Arias J, Brum WS, Salvadó G, Therriault J, Servaes S, Wang YT, et al. Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum. Brain. 2025;148(7):2384-2399. doi:10.1093/brain/awaf033

BibTeX
@article{FernndezArias2025,
  author = {Fernández Arias, Jaime and Brum, Wagner S and Salvadó, Gemma and Therriault, Joseph and Servaes, Stijn and Wang, Yi-Ting and Aumont, Etienne and Rahmouni, Nesrine and Macedo, Arthur C and Quispialaya, Kely Monica and Hosseini, Seyyed Ali and Kunach, Peter and Jia, Wan Lu and Chan, Tevy and Trudel, Lydia and Hall, Brandon and Zheng, Yanseng and Mohapatra, Sejal and Mathotaarachchi, Sulantha S and Vitali, Paolo and Tissot, Cécile and Bezgin, Gleb and Iturria-Medina, Yasser and Ashton, Nicholas J and Benedet, Andréa Lessa and Karikari, Thomas K and Triana-Baltzer, Gallen and Klostranec, Jesse M and Kolb, Hartmuth C and Zimmer, Eduardo R and Janelidze, Shorena and Mattsson-Carlgren, Niklas and Stomrud, Erik and Palmqvist, Sebastian and Zetterberg, Henrik and Blennow, Kaj and Pascoal, Tharick and Montembeault, Maxime and Hansson, Oskar and Rosa-Neto, Pedro},
  title = {Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum},
  journal = {Brain},
  year = {2025},
  volume = {148},
  number = {7},
  pages = {2384--2399},
  doi = {10.1093/brain/awaf033}
}
Kostenlos starten →